DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for syphilis — screening already-approved drugs against its 5-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSyphilis maps to a 5-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for syphilis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
matrix metallopeptidase 7 (MMP7) — MMP7 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2Y6D · 1.6 Å · ligand N-[(2S)-1-[4-(5-BROMOPYRIDIN-2-YL)PIPERAZIN-1-YL]SULFONYL-5-PYRIMIDIN-2-YL-PENTAN-2-YL]-N-HYDROXY-METHANAMIDE (TQJ). Experimental structure, not a prediction.
What the evidence adds up to
Penicillin became standard therapy for syphilis within four years of the first published report of its use, based on widespread experimental and clinical research. By 1955, follow-up studies had confirmed that penicillin was the drug of choice for all types of syphilis, valued for ease of administration and lack of toxicity. Retreatment was recommended in cases of clinical relapse, progression, or serorelapse, and proper patient observation was required to detect these failures.
Despite this established treatment, syphilis continues to be an important epidemiologic problem, with a steady increase in incidence observed for several years. The 2013 review, based on European (IUSTI) and U.S. (CDC) guidelines, presents selected practical issues for diagnosis and treatment but provides no new trial data, no response rates, and no survival figures. It is a summary of existing guidelines, not an original study.
No abstract reports any new drug being tested against syphilis, nor any repurposing attempt. The abstracts contain no numbers — no sample sizes, no cure rates, no survival data. The only concrete claim is that penicillin works and is standard, yet the disease incidence continues to rise. What is still missing is any explanation for the ongoing increase despite an effective drug, and any evidence that current diagnostic or treatment strategies are being improved or adapted to reverse that trend.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Advances in Dermatology and Allergology · 2013 · 43 citations · open access
Current standards for diagnosis and treatment of syphilis: selection of some practical issues, based on the European (IUSTI) and U.S. (CDC) guidelines
AbstractSyphilis continues to be an important epidemiologic problem. For a few years a steady increase in the incidence of this sexually transmitted disease has been observed. Advances in medical science obligate the doctor to use only such diagnostic and therapeutic approaches that are scientifically proven. Based on the European (IUSTI) and U.S. (CDC) guidelines, in this manuscript, we present some selected practical issues concerning diagnosis and treatment of syphilis. We truly hope that the present review will help all doctors taking care of syphilitic patients to systematize the current knowledge.
New England Journal of Medicine · 1948 · 2 citations
Syphilis
AbstractAT THE time of this writing it is approximately four years since the publication of the first report on the use of penicillin in the treatment of syphilis.1 The remarkable efficacy of this drug in combating man's most crippling venereal disease is attested by the fact that in so short a time it has become accepted as standard therapy for syphilis. A vast effort has been expended in widespread and well organized research projects, both experimental and clinical. From ten to twenty years are required to evaluate properly the therapeutic results of any approach to syphilis in all respects except . . .
New England Journal of Medicine · 1955 · 0 citations
Syphilis
AbstractTherapyThe worth of penicillin as an agent for the management of all types of syphilis has been established. The end results of intensive follow-up studies have confirmed the initial impressions of the conservative syphilologists. Penicillin is the drug of choice because of its ease of administration and nontoxicity. Retreatment should be instituted in the face of an obvious clinical relapse or progression. Serorelapse should also be considered an indication for further therapy. These failures can only be determined by the proper observation of the patient. Once treatment is instituted the patient must be followed and all the persons known . . .
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
